Literature DB >> 7214322

Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.

H Rosenfeld, J Roberts.   

Abstract

Mouse P388 and L1210 leukemia cells grown in vitro were found to be 4 to 10 times more sensitive to 6-diazo-5-oxo-L-norleucine and 3 to 5 times more sensitive to Acivicin than were 3T3 and C57BL x DBA/2 F1 embryonic fibroblasts. The combined actions of succinylated Acinetobacter glutaminase-asparaginase and 6-diazo-5-oxo-L-norleucine or Acivicin produced synergistic inhibition of nucleic acid synthesis in P388 tumor cells. An uptake system for Acivicin is described. Its properties in P388 and 3T3 cells are similar in their strong temperature dependence, utilization of the "L" transport system, presumably competitive inhibition by glutamine, similar Km's (about 200 microM), and potent inhibition by p-chloromercuribenzene sulfonate, NA+. However, Acivicin uptake was inhibited in 3T3 (but not in P388) cells by KCN or 2,4-dinitrophenol. At equilibrium in P388 cells, the intracellular level of Acivicin was approximately 57-fold greater than was the extracellular concentration. The accumulated Acivicin was not metabolized by P388 cells, nor does exchange of 3H label into water occur. Rapid efflux of Acivicin occurred with both cell lines at 37 degrees, but efflux from 3T3 cells was greatly diminished at 0 degrees. The rate of efflux was accelerated by including glutamine or unlabeled Acivicin in the extracellular medium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214322

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

Review 2.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

3.  Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and Tretinoin.

Authors:  G K Górski; L E McMorrow; M H Donaldson
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

4.  Inhibition of tumor cell glutamine uptake by isolated neutrophils.

Authors:  D B Learn; E L Thomas
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

Review 5.  Targeting metabolic transformation for cancer therapy.

Authors:  Daniel A Tennant; Raúl V Durán; Eyal Gottlieb
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

6.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 7.  Metabolism and brain cancer.

Authors:  Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Predicting selective drug targets in cancer through metabolic networks.

Authors:  Ori Folger; Livnat Jerby; Christian Frezza; Eyal Gottlieb; Eytan Ruppin; Tomer Shlomi
Journal:  Mol Syst Biol       Date:  2011-06-21       Impact factor: 11.429

9.  Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.

Authors:  K R Huber; E P Mayer; D F Mitchell; J Roberts
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

Review 10.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.